[Skip to Content]
[Skip to Content Landing]
Comment & Response
September 10, 2014

Idiopathic Intracranial Hypertension

Author Affiliations
  • 1Department of Neurotrauma and Neurodegeneration, University of Birmingham, Birmingham, England
  • 2Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, England
  • 3Birmingham Neuro-Ophthalmology Unit, University Hospitals Birmingham NHS Trust, Birmingham, England
JAMA. 2014;312(10):1059-1060. doi:10.1001/jama.2014.8894

To the Editor The Idiopathic Intracranial Hypertension Treatment Trial1 evaluated the use of acetazolamide vs placebo in conjunction with a weight-reducing, low sodium diet in adults with idiopathic intracranial hypertension (IIH). Although the authors stated “there are no properly designed clinical trials,” the widespread use of acetazolamide has been questioned since the results of the first randomized controlled trial2 that did not demonstrate benefit of acetazolamide in IIH, although it was underpowered.